openPR Logo
Press release

Cancer Angiogenesis Inhibitors Market Sales Revenue Clinical Trials Pipeline Report

06-30-2017 12:20 PM CET | Health & Medicine

Press release from: Kuick Resarch

Cancer Angiogenesis Inhibitors Market Sales Revenue Clinical

Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70 percent of the world’s cancer deaths also occur in these regions. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.

Download Report:

https://www.kuickresearch.com/report-Global-Cancer-Angiogenesis-Inhibitors-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight"
Table of Contents

1. Angiogenesis: History and Quest for Treatment

2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention
2.1 Hallmarks of Cancer
2.1.1 Self Sufficiency in Growth Signals
2.1.2 Insensitivity to Antigrowth Signals
2.1.3 Acquired Capability: Evading Apoptosis
2.1.4 Limitless Replicative Potential
2.1.5 Sustained Angiogenesis
2.1.6 Tissue Invasion & Metastasis
2.2 Angiogenic- Metastatic Pathway as a Target for Anti-Cancer Therapies

3. What is Angiogenesis?
3.1 Stages of Angiogenesis
3.2 Types of Angiogenesis
3.2.1 Sprouting Angiogenesis
3.2.2 Intussusceptive Angiogenesis or Splitting Angiogenesis

4. Modulators of Angiogenesis
4.1 VEGF & Angiogenesis
4.2 Platelet Derived Growth Factor
4.3 Fibroblast Growth Factors (FGFs) & FGF Receptors
4.4 Endothelins & Endothelin Receptors
4.5 Erythropoietin & Erythropoietin Receptor
4.6 Angiopoietins & Tie2 Receptor

5. Mechanism of Angiogenesis
5.1 Dilation of Existing Vessels, Increase in Vascular Permeability & Degradation of Existing Vessels
5.2 Endothelial Cells Proliferation & Migration
5.3 Assembling of Endothelial Cells, Formation of Cords & Lumen
5.4 Long-Term Survival of Vascular Endothelium
5.5 Differentiation of Vascular Endothelium to Meet Local Needs

6. Classification of Angiogenesis Inhibitors
6.1 Direct Endogenous Inhibitors of Angiogenesis
6.2 Indirect Inhibitors of Angiogenesis
6.3 Conventional Chemotherapeutic Agents
6.4 VEGF Targeted Therapy
6.5 FGF Targeted Therapies
6.6 Oncogene Targeted Therapy
6.7 Matrix Degrading & Remodeling Targeted Therapy
6.8 Stromal Tumor Associated Cell Targeted Therapy
6.9 Cell Adhesion Molecules (CAMs) Targeted Therapy
6.10 Inflammatory Angiogenesis Targeted Therapy

7. Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy

8. Applications of Angiogenesis Inhibitors
8.1 Quantitation & Prognosis of Malignant Disorders
8.2 Antiangiogenic Therapies
8.2.1 Cancer
8.2.2 Interferon Alpha-2α to Treat Hemangiomas
8.2.3 Ocular Neovascularization

9. Global Angiogenesis Inhibitors Market overview
9.1 Current Market Scenario
9.2 Global Cancer Angiogenesis Inhibitors Clinical Pipeline Overview

10. Global Cancer Angiogenesis Inhibitors Market Dynamics
10.1 Favorable Market Parameters
10.1.1 Large Global Patient Pool
10.1.2 Severity of the Disease
10.1.3 Side Effects of the Existing Drugs
10.1.4 Unmet Requirement of Completely Curative Agents
10.2 Major Challenges of Cancer Angiogenesis Inhibitors Market
10.2.1 Difficulties Associated with Evaluation of Anti Angiogenic Effect of Drugs
10.2.2 Prospects of Delayed Toxicity with Long-Term Anti-Angiogenic Therapy
10.2.3 Need of the Better Therapy Models
10.2.4 Approval from Regulatory Guidelines: A Major Challenge
10.2.5 Journey of Drug from Bench to Bedside: A Matter of Money & Time

11. Concluding Remarks & Future Market Prospects

12. Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration

13. Marketed Cancer Angiogenesis Inhibitors Clinical Insight by Company & Indication
13.1 Apatinib
13.2 Lenalidomide (Ladevina & Revlimid)
13.3 Pomalidomide (Imnovid & Pomalyst)
13.4 Sorafenib (Nexavar)
13.5 Thalidomide (Thaled, Thalidomide Celgene & Thalomid)
13.6 Pazopanib (Votrient)
13.7 Bevacizumab (Avastin)
13.8 Bevacizumab Biosimilar (Cizumab)
13.9 Cetuximab (Erbitux)
13.10 Axitinib (Inlyta)
13.11 Recombinant Human Endostatin (Endostar & Endu)

14. Discontinued & Suspended Cancer Angiogenesis Inhibitors Clinical Pipeline by Company & Phase
14.1 No Development Reported
14.2 Discontinued
14.3 Suspended

15. Competitve Landscape
15.1 Advenchen Laboratories
15.2 Allergan
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Angstrom Pharmaceuticals
15.6 Acceleron Pharma
15.7 Biocon
15.8 Bionomics
15.9 CASI Pharmaceuticals
15.10 Celgene Corporation
15.11 Enzon Pharmaceuticals
15.12 Five Prime Therapeutics
15.13 Fujifilm Kyowa Kirin Biologics
15.14 Genentech
15.15 Genexine
15.16 Hetero Drugs
15.17 ImClone Systems
15.18 Intas Pharmaceuticals
15.19 Kyowa Hakko Kirin
15.20 Levolta Pharmaceuticals
15.21 Mabtech
15.22 Marsala Biotech
15.23 Neumedicines
15.24 Novartis
15.25 Oncobiologics
15.26 Onyx Pharmaceuticals
15.27 Pfizer
15.28 Philogen
15.29 TBG Diagnostics
15.30 Reliance Life Sciences
15.31 Roche
15.32 Samsung Bioepis
15.33 Simcere Pharmaceutical
15.34 SynCore Biotechnology
15.35 TaiRx
15.36 Taiwan Liposome
15.37 Tiltan Pharma
15.38 XBiotech

Figure 3-1: Different Stages of Involved in Angiogenesis
Figure 3-2: Different Types of Angiogenesis
Figure 3-3: Steps Involved in Sprouting Angiogenesis
Figure 3-4: Steps Involved in Splitting Angiogenesis
Figure 4-1: Different Types of Modulators of Angiogenesis
Figure 4-2: Pathway Followed by VEGF during Angiogenesis
Figure 4-3: Modulatory Pathway of FGF in Angiogenesis
Figure 4-4: Basic Pathway Followed by Modulators to Facilitate Angiogenesis
Figure 5-1: Mechanism of Angiogenesis Stimulated by Tumor Cells
Figure 6-1: Various Categories of Angiogenesis Inhibitors
Figure 8-1: Important Applications of Angiogenic Inhibitors
Figure 9-1: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (%), 2016
Figure 9-2: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (Numbers), 2016
Figure 9-3: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (%), 2016
Figure 9-4: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (Numbers), 2016
Figure 10-1: Favorable Parameters for Cancer Angiogenesis Inhibitors Market
Figure 10-2: Major Challenges of Cancer Angiogenesis Inhibitors Market
Figure 15-1: Advenchen Laboratories - Clinical Pipeline
Figure 15-2: Alexion Pharmaceuticals - Clinical Pipeline
Figure 15-3: Alnylam Pharmaceuticals – Clinical Pipeline
Figure 15-4: Amgen - Clinical Pipeline
Figure 15-5: Acceleron Pharma – Clinical Pipeline
Figure 15-6: Biocon - Clinical Pipeline
Figure 15-7: Bionomics – Clinical Pipeline
Figure 15-8: Casi Pharmaceutical - Clinical Development
Figure 15-9: Celgene - Clinical Pipeline
Figure 15-10: Five Prime Therapeutics – Clinical Pipeline
Figure 15-11: Fujifilm Kyowa Kirin Biologics - Clinical Pipeline
Figure 15-12: Genexine - Clinical Pipeline
Figure 15-13: Levolta Pharmaceuticals – Clinical Pipeline
Figure 15-14: Neumedicines - Clinical Pipeline
Figure 15-15: Novartis - Clinical Pipeline
Figure 15-16: Oncobiologics - Clinical Pipeline
Figure 15-17: Philogen – Clinical Pipeline
Figure 15-18: Samsung Bioepis - Clinical Pipeline
Figure 15-19: Simcere Pharmaceutical Group – Clinical Pipeline
Figure 15-20: SynCore Biotechnology – Clinical Pipeline

Table 1-1: List of the Major Events in History of Angiogenesis Inhibitors Development
Table 2-1: List of FDA Approved Drugs & Their Target Cancer
Table 4-1: List of Some Angiogenesis Inhibitors & Their Target Receptors

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Angiogenesis Inhibitors Market Sales Revenue Clinical Trials Pipeline Report here

News-ID: 603595 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Angiogenesis

Global Angiogenesis Modulators Market, Global Angiogenesis Modulators Industry, …
The Angiogenesis Modulators market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The Global Angiogenesis Modulators Market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Angiogenesis Modulators market. The report focuses on well-known providers in the global
Angiogenesis Assay Market: Competitive Dynamics & Global Outlook 2024
LP INFORMATION offers a latest published report on Angiogenesis Assay Market Analysis and Forecast 2019-2024 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Angiogenesis Assay market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,
Angiogenesis Assay Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Angiogenesis Assay Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Angiogenesis Assay players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Angiogenesis Assay with respect to individual growth
Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight Report
“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights: * Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy * Modulators & Mechanism of Angiogenesis * Classification of Angiogenesis Inhibitors * Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy * Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase * Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs * Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs Download Report Sample Weblink: https://www.kuickresearch.com/report-Global-Cancer-Angiogenesis-Inhibitors-Market-&-Clinical-Pipeline-Insight.php For Report
Global Cancer Angiogenesis Inhibitors Market & Ongoing Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Angiogenesis: History and Quest for Treatment 2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention 2.1 Hallmarks of Cancer 2.1.1 Self Sufficiency in Growth Signals 2.1.2 Insensitivity to Antigrowth Signals 2.1.3 Acquired Capability: Evading Apoptosis 2.1.4 Limitless Replicative Potential 2.1.5 Sustained Angiogenesis
Global Cancer Angiogenesis Inhibitors Market & Ongoing Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Angiogenesis: History and Quest for Treatment 2. Angiogenesis Inhibitors: An Ounce of Cure & Prevention 2.1 Hallmarks of Cancer 2.1.1 Self Sufficiency in Growth Signals 2.1.2 Insensitivity to Antigrowth Signals 2.1.3 Acquired Capability: Evading Apoptosis 2.1.4 Limitless Replicative Potential 2.1.5 Sustained Angiogenesis